Ensifentrine improves lung function – Verona Pharma

Tuesday 9 August 2022

United Kingdom

A small molecule drug designed to improve lung function has met the primary and secondary endpoints in a Phase 3 trial of patients with chronic obstructive pulmonary disease (COPD), the developer Verona Pharma Plc announced on 9 August. The drug, ensifentrine, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4, a mode of action that enables it to combine both bronchodilator and anti-inflammatory effects in a single compound.